Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2020 10:27 ET | Source: Revive Therapeutics Ltd.

UPDATE - Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty life sciences company focused on the research and development...
July 31, 2020 08:39 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
June 30, 2020 15:45 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
June 12, 2020 08:09 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
June 09, 2020 12:06 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

TORONTO, June 09, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
June 03, 2020 11:09 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
May 13, 2020 09:36 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
April 29, 2020 08:24 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

TORONTO, April 29, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
April 23, 2020 08:38 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

TORONTO, April 23, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
April 21, 2020 11:22 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

TORONTO, April 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...